Indications for: LIPIODOL
For use in: hysterosalpingography in adults, selective hepatic intra-arterial use for imaging tumors in adults with hepatocellular carcinoma (HCC), or lymphography in children and adults.
See full labeling. Hysterosalpingography: inject in 2mL increments into endometrial cavity with fluoroscopic control until tubal patency determined; re-image after 24hrs to establish contrast agent has entered peritoneal cavity. Lymphography: inject into lymphatic vessel over ≥1.25hrs (max rate 0.2mL/min) under radiologic monitoring; re-image after 24 or 48hrs to evaluate nodal architecture; (upper extremities): inject 2–4mL; (lower extremities): 6–8mL; (penile): 2–3mL; (cervical): 1–2mL. HCC: inject 1.5–15mL (based on tumor size) slowly under radiologic monitoring; discontinue when stagnation or reflux evident; max dose 20mL.
See full labeling. Lymphography: inject 1–6mL according to anatomical area; max 0.25mL/kg.
Hysterosalpingography: pregnancy, intrauterine bleeding and endocervicitis, acute pelvic inflammatory disease, marked cervical erosion, immediate pre- or postmenstrual phase or within 30 days of curettage or conization or known or suspected reproductive tract neoplasia. Lymphography: right to left cardiac shunt, advanced pulmonary disease, tissue trauma or hemorrhage advanced neoplastic disease with expected lymphatic obstruction, previous surgery interrupting the lymphatic system, radiation therapy to examined area. HCC: areas of liver where bile ducts are dilated unless external biliary drainage performed prior to injection. For all: hyperthyroidism, traumatic injuries, and recent hemorrhage or bleeding.
For intralymphatic, intrauterine and selective hepatic intra-arterial use only.
Severely impaired lung function, cardiorespiratory failure, right-sided cardiac overload, sensitivity to other iodinated contrast agents, bronchial asthma, allergic disorders: avoid. Perform radiological monitoring during injection. Avoid intravasation. Monitor for hypersensitivity reactions during and for ≥30mins after administration. Exacerbation of portal hypertension, hepatic ischemia, hepatic failure. Do not exceed recommended dose. Monitor thyroid function for several months after completion. Screen for renal dysfunction prior to intra-arterial use; consider follow-up assessments if history of renal dysfunction. Pregnancy; exclude status within 24hrs prior to initiation (for hysterosalpingography). Nursing mothers: consider thyroid function testing.
Radiopaque contrast agent.
May interfere with iodine-based diagnostic tests and radiotherapy.
Hypersensitivity reactions, pulmonary embolism, pulmonary dysfunction, exacerbation of liver disease, procedural complications, abdominal pain, fever, nausea, vomiting, thyroid dysfunction.
Generic Drug Availability: